1. Purpose

Cerebral palsy is a term which includes a number of different diseases or condition that can arise any time during brain development. Approximately 45% of all cases of cerebral palsy are associated with preterm birth (Australian Cerebral Palsy Register Report December 2009) with the rate of cerebral palsy amongst neonatal survivors born at less than 28 weeks gestation up to 30 times higher compared with infants born at term.

Theoretically magnesium sulphate (MgSO4) might be neuroprotective due to effects on cellular metabolism, cell death or injury or blood flow to the brain. The first case control study was published fifteen years ago and the evidence has been growing ever since (Nelson et al, 1995). The current Cochrane review concludes that antenatal MgSO4 given to women at risk of preterm birth substantially reduces the risk of cerebral palsy in their child (RR 0.68 95% confidence interval 0.54 to 0.87; five trials, 6145 infants). This Cochrane review contains five trials: Mittendorf et al, 2002; The Magpie Trial 2002; Crowther et al, 2003; Marret et al, 2007; Rouse et al, 2008. Two meta-analysis were published recently (Costantine et al; Doyle et al). National Clinical Practice Guidelines were released in March 2010.

This clinical guideline outlines the requirement for the use of Magnesium Sulphate to a woman at risk of preterm birth to prevent cerebral palsy in their child at the Women’s.

2. Definitions

Not applicable.

3. Responsibilities

Staff caring for a woman at risk of preterm birth should be aware about this guideline.

4. Guideline

4.1 Recommendations for use

The use of MgSO4 is recommended for neuroprotection of the fetus/infant/child:

- when women are at risk of imminent preterm birth before 30 weeks gestation
- when preterm birth before 30 weeks gestation is planned or definitely expected within 24 hours.

The use of MgSO4 is recommended:

- regardless of the number of babies in utero
- regardless of the anticipated mode of birth
- whether or not antenatal corticosteroids have been given.

4.2 Dose

When birth is planned commence MgSO4 as close to four hours before birth as possible.

Note: Ensure magnesium sulphate is administered concurrently via a Y-site with a compatible IV fluid.

Loading dose: using a 10ml vial of MgSO4 prepare 4gram (i.e. 8ml) of magnesium sulphate 50% in a 10mL syringe, configure pump to accept the 10mL syringe and set the pump to 32mL an hour for 15 minutes.

Maintenance: once the loading dose has been completed, using the 50mL vial of magnesium sulphate, magnesium sulphate 50% in a 50mL syringe, re-set the pump to accept 50mL syringe and set the pump to administer the maintenance rate of 1g/hr (2mL/hour) or as ordered.

Continue the regime until birth or 24 hours, whichever comes first.

Urgent delivery: In situations where urgent delivery is necessary because of actual or imminent maternal or fetal compromise then delivery should not be delayed to administer MgSO4.
Repeat doses: In the event that birth does not occur after giving MgSO₄ for neuroprotection of the infant, and preterm birth (less than 30 weeks gestation) again appears imminent (planned or definitely expected within 24 hours), a repeat dose of MgSO₄ may be considered.

4.3 Monitoring

Magnesium level monitoring
Measurement of magnesium levels will facilitate management where there are signs of toxicity or in the presence of renal impairment.

Serum magnesium concentrations should be checked every 6 hours in the antepartum and intrapartum phase (therapeutic level of magnesium: 1.7 to 3.5 mmol/L).

Magnesium is excreted by the kidneys and regular monitoring of serum levels should be conducted in women with oliguria (urine output <100mL over 4 hours) or urea >10mmol/L and those with renal impairment.

<table>
<thead>
<tr>
<th>Mg conc (mmol/L)</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8 - 1.0</td>
<td>Normal plasma level</td>
</tr>
<tr>
<td>1.7 - 3.5</td>
<td>Therapeutic range</td>
</tr>
<tr>
<td>2.5 - 5.0</td>
<td>ECG changes (P-Q interval prolongation, widen QRS complex)</td>
</tr>
<tr>
<td>4.0 – 5.0</td>
<td>Reduction in deep tendon reflexes</td>
</tr>
<tr>
<td>&gt; 5.0</td>
<td>Loss of deep tendon reflexes</td>
</tr>
<tr>
<td>&gt; 7.5</td>
<td>Sinoatrial and atrioventricular blockage. Respiratory paralysis and CNS depression</td>
</tr>
<tr>
<td>&gt; 12</td>
<td>Cardiac arrest</td>
</tr>
</tbody>
</table>

Note: If serum magnesium level is >3.5mmol/L, cease infusion and consult with obstetrician.

Clinical observations

During administration of the loading or bolus dose:
- 5 minutely blood pressure and pulse (x 4 readings)
- observe for the development of side effects
- check patellar reflexes after administration.

During administration of the maintenance infusion:
- ½ hourly blood pressure, pulse, and respiratory rate (pre-treatment respiratory rate should be ≥ 16per minute). These may be undertaken hourly post-birth.
- 1 hourly patellar reflexes
- 1 hourly urine measures, 4 hourly testing of urinary protein
- 2 hourly temperature
- continuous electronic fetal monitoring from 26 weeks gestation until clinical review/discussion by medical staff. Between 24- 26 weeks gestation, individualised management with regard to fetal monitoring will be considered
- maintain strict fluid balance chart.

Record patellar reflexes as:
- A = Absent
Guideline

Magnesium Sulphate - Neuroprotection of Preterm Infants

- N = Normal
- B = Brisk.

Request magnesium level and review management if:
- respiratory rate < 12 breaths/minute
- urine output < 100mLs in 4 hours
- loss of patellar reflexes
- further seizures occur.

Response to magnesium toxicity:
The following clinical signs of magnesium toxicity must be reviewed by a consultant obstetrician/anaesthetist:
- urine output <100mL in 4 hours
- absent patellar reflexes
- respiratory depression.

The antidote for magnesium toxicity is: 10mL calcium gluconate available as 2.2 mmol calcium in 10mL vial (formerly known as 10% solution) over 10 minutes by slow intravenous injection. The patient requires ECG monitoring during and after administration because of the potential for cardiac arrhythmias.

Resuscitation and ventilator support should be available during and after dose administration of both magnesium sulphate and calcium gluconate.

CEASE Magnesium infusion in the following emergencies:
- respiratory arrest: call: Code Blue - Adult and Child (intranet)

4.4 Potential interactions
There is a potential theoretical interaction between MgSO₄ and nifedipine resulting in hypotension and neuromuscular blockade effects. This is seldom reported in clinical practice (Snyder & Cardwell, 1989; Ben-Ami et al, 1994). If hypotension occurs, nifedipine and MgSO₄ administration should be ceased.

5. Evaluation, monitoring and reporting of compliance to this guideline
Compliance to this guideline will be monitored by review of incidents reported through VHIMS.

6. References
See Evidence Table over the page.
Guideline

Magnesium Sulphate - Neuroprotection of Preterm Infants

PGP Disclaimer Statement

The Royal Women's Hospital Clinical Guidelines present statements of ‘Best Practice’ based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women's this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it.

Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women's Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated.

In view of the possibility of human error and / or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site.

You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner.

NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines.
## Evidence Table

<table>
<thead>
<tr>
<th>Author/s</th>
<th>Title</th>
<th>Source</th>
<th>Level of Evidence</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crowther CA, Hiller JE, Doyle LW, Haslam RR for the Australasian Collaborative Trial of Magnesium sulphate (ACTO MgSO4) Collaborative Group.</td>
<td>Effect of magnesium sulphate given for neuroprotection before preterm birth a randomised controlled trial.</td>
<td>JAMA 2003;290:2669-2676.</td>
<td>II RCT</td>
<td>n =1,064</td>
</tr>
</tbody>
</table>
### Guideline

**Magnesium Sulphate - Neuroprotection of Preterm Infants**

<table>
<thead>
<tr>
<th>Author/s</th>
<th>Title</th>
<th>Source</th>
<th>Level of Evidence</th>
<th>Comments</th>
</tr>
</thead>
</table>

7. **Legislation/Regulations related to this guideline**

Not applicable.

8. **Appendices**

Not applicable.